Biontech expands clinical oncology portfolio with first patient dosed in phase 2 trial of mrna-based individualized immunotherapy bnt122 in colorectal cancer patients

Mainz, germany, october 1, 2021 (globe newswire) – biontech se (nasdaq: bntx, “biontech” or “the company”), announced today that the first colorectal cancer patient has been treated with its individualized mrna cancer vaccine bnt122 (autogene cevumeran, ro7198457) in a phase 2 clinical trial. the trial has been initiated in the united states, germany, spain and belgium. it is planned to enroll about 200 patients to evaluate the efficacy of ro7198457 (bnt122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. as the second deadliest cancer worldwide, the medical need for novel therapies to treat colorectal cancer remains high.
BNTX Ratings Summary
BNTX Quant Ranking